CG Oncology BOND-003 Shows Remarkable Durability at 24 Months
Cretostimogene reported a 24-month complete response rate of 41.8% (46/110) in BCG‑unresponsive high‑risk NMIBC, with 75.5% achieving a CR...
Hutchmed Highlights Successful New Lung Cancer Data for 2025
HUTCHMED will take a data-light but strategy-heavy slate to WCLC and CSCO next week, led by updated analyses from...
HUTCHMED Highlights New Lung Cancer Data at 2025 Conferences
HUTCHMED will use next week’s oncology meetings to surface a broad slate of lung and solid tumor readouts, led...
Successful Myriad MRD Clinical Data in The Lancet Oncology
Median systemic therapy–free survival split along ctDNA status in a Phase 2 oligometastatic clear-cell RCC study: patients with ctDNA-positive...
Breakthrough AVIM Data: Sustained Blood Pressure Reduction
Topline data: In long-term follow-up of MODERATO II participants (n=16; mean 3.6 years), atrioventricular interval modulation (AVIM) maintained a...
Indaptus Therapeutics Provides Latest Clinical Trial Update
Topline: In the Phase 1 INDP-D101 study of Decoy20, a single urothelial cancer patient with liver metastases achieved a...
Silexion Selects CRO for Upcoming SIL204 Phase 2/3 Trials
SIL204 delivered up to 97% inhibition in KRAS Q61H pancreatic cancer cells and roughly 90% inhibition in colorectal models,...
Preclinical Data Supports CNM-Au8 for Parkinson’s Disease
In a human neuron model of Parkinson’s disease, CNM-Au8 improved mitochondrial membrane potential and volume while reducing reactive oxygen...
New SIK3 Inhibitor Approved For Autoimmune Disease Trial
Belgium has approved a first‑in‑human study of Onco3R Therapeutics’ SIK3‑selective inhibitor O3R‑5671, clearing a single‑ and multiple‑ascending dose trial...
New Meta-Analysis: GeneSight Test Improves Depression Outcomes
Across six prospective controlled studies totaling 3,532 adults with major depressive disorder and at least one prior treatment failure,...